These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 19663667)

  • 21. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
    Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
    N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer.
    Link JS; Waisman JR; Nguyen B; Jacobs CI
    Clin Breast Cancer; 2007 Oct; 7(10):779-83. PubMed ID: 18021479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
    Nisticò C; Bria E; Vaccaro V; Cuppone F; Fornier M; Sperduti I; Carpino A; Izzo F; Tropea F; Cognetti F; Terzoli E
    Anticancer Drugs; 2009 Feb; 20(2):109-14. PubMed ID: 19209027
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA; Raefsky E; Castillo R; Lahiry A; Locicero R; Thompson D; Shastry M; Burris HA; Hainsworth JD
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].
    Mychaluk J; Piprot C; Sevestre H; Merviel P; Gondry J; Fauvet R
    Presse Med; 2009 Sep; 38(9):1370-4. PubMed ID: 19349140
    [No Abstract]   [Full Text] [Related]  

  • 26. Bevacizumab in the treatment of breast cancer.
    Koutras AK; Fountzilas G; Makatsoris T; Peroukides S; Kalofonos HP
    Cancer Treat Rev; 2010 Feb; 36(1):75-82. PubMed ID: 19932567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab improves the delivery and efficacy of paclitaxel.
    Yanagisawa M; Yorozu K; Kurasawa M; Nakano K; Furugaki K; Yamashita Y; Mori K; Fujimoto-Ouchi K
    Anticancer Drugs; 2010 Aug; 21(7):687-94. PubMed ID: 20559127
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
    Huober J; Fasching PA; Hanusch C; Rezai M; Eidtmann H; Kittel K; Hilfrich J; Schwedler K; Blohmer JU; Tesch H; Gerber B; Höß C; Kümmel S; Mau C; Jackisch C; Khandan F; Costa SD; Krabisch P; Loibl S; Nekljudova V; Untch M; Minckwitz Gv
    Eur J Cancer; 2013 Jul; 49(10):2284-93. PubMed ID: 23541564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer.
    Mirtsching B; Cosgriff T; Harker G; Keaton M; Chidiac T; Min M
    Clin Breast Cancer; 2011 Apr; 11(2):121-8. PubMed ID: 21569998
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer.
    Karachaliou N; Saloustros E; Vamvakas L; Mavroudis D; Georgoulias V
    Ann Oncol; 2010 Aug; 21(8):1729-1730. PubMed ID: 20601370
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects of chemotherapy on circulating angiogenic factor levels in patients with breast cancer].
    Tang JH; Zhao JH; Gong JP; Qin JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):210-4. PubMed ID: 17649639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy.
    Chen JH; Mehta RS; Carpenter PM; Nalcioglu O; Su MY
    J Clin Oncol; 2007 Dec; 25(35):5667-9. PubMed ID: 18065744
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of vascular endothelial growth factor genetic variability in cancer.
    Schneider BP; Radovich M; Miller KD
    Clin Cancer Res; 2009 Sep; 15(17):5297-302. PubMed ID: 19706811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Beatty GL; Giantonio BJ
    Expert Rev Anticancer Ther; 2008 May; 8(5):683-8. PubMed ID: 18471041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Anti-VEGF therapy with bevacizumab in breast cancer].
    Tóth J; Gonda A; Szántó J
    Lege Artis Med; 2008 Oct; 18(10):669-73. PubMed ID: 19227609
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor ‑634G/C polymorphism is associated with increased breast cancer risk and aggressiveness.
    Sa-Nguanraksa D; Chuangsuwanich T; Pongpruttipan T; Kummalue T; Rojananin S; Ratanawichhitrasin A; Prasarttong-Osoth P; Chuthatisith S; Pisarnturakit P; Aeumrithaicharoenchok W; Rushatamukayanunt P; Lohsiriwat V; Boonsripitayanon M; Malasit P; O-Charoenrat P
    Mol Med Rep; 2013 Oct; 8(4):1242-50. PubMed ID: 23904001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.
    Allegrini G; Coltelli L; Orlandi P; Fontana A; Camerini A; Ferro A; Cazzaniga M; Casadei V; Lucchesi S; Bona E; Di Lieto M; Pazzagli I; Villa F; Amoroso D; Scalese M; Arrighi G; Molinaro S; Fioravanti A; Finale C; Triolo R; Di Desidero T; Donati S; Marcucci L; Goletti O; Del Re M; Salvadori B; Ferrarini I; Danesi R; Falcone A; Bocci G
    Pharmacogenomics; 2014 Dec; 15(16):1985-99. PubMed ID: 25521357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
    Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.
    Philippin-Lauridant G; Thureau S; Ouvrier MJ; Blot E
    Ann Oncol; 2008 Nov; 19(11):1977-8. PubMed ID: 18801882
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.